(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
25 March 2010 (25.03.2010)

PCT

(10) International Publication Number
WO 2010/033444 A8

(51) International Patent Classification:
C07D 417/14 (2006.01) *A61P 31/12* (2006.01)
A61K 31/4709 (2006.01)

(21) International Application Number:
PCT/US2009/056772

(22) International Filing Date:
14 September 2009 (14.09.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/097,291 16 September 2008 (16.09.2008) US
61/150,826 9 March 2009 (09.03.2009) US

(71) Applicant *(for all designated States except US)*: **BOEHRINGER INGELHEIM INTERNATIONAL GMBH** [DE/DE]; Binger Strasse 173, 55216 Ingelheim (DE).

(72) Inventors; and


(75) Inventors/Applicants *(for US only)*: **BERKENBUSCH, Thilo** [DE/DE]; Boehringer Ingelheim International GmbH, Binger Strasse 173, 55216 Ingelheim (DE). **BUSACCA, Carl Alan** [US/US]; Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, Connecticut 06877-0368 (US). **JAEGER, Burkhard** [DE/DE]; Boehringer Ingelheim International GmbH, Binger Strasse 173, 55216 Ingelheim (DE). **VARSOLONA, Richard J.** [US/US]; Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, Connecticut 06877-0368 (US).

(74) Agents: **MORRIS, Michael P.** et al.; Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT 06877-0368 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,

[Continued on next page]

(54) Title: CRYSTALLINE FORMS OF A 2-THIAZOLYL- 4-QUINOLINYL-OXY DERIVATIVE, A POTENT HCV INHIBITOR



(1)

(57) Abstract: This invention relates to novel crystalline forms of the following Compound (1), and the sodium salt thereof, and methods for the preparation thereof, pharmaceutical compositions thereof, and their use in the treatment of Hepatitis C Viral (HCV) infection.

WO 2010/033444 A8

CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

(48) Date of publication of this corrected version:
17 June 2010

(15) Information about Correction:
see Notice of 17 June 2010